FAST NEWS: InnoCare Pharma’s Loss Soars on R&D Costs, Exchange Losses
The latest: InnoCare Pharma Ltd. (9969.HK) said it expects to report its net loss soared about 13 times to 910 million yuan ($134 million) last year, according to a profit…
RELATED ARTICLES
-
Everest Medicines eyes mRNA tumor vaccines as drug valuations rebound
1952.HK - Innogen Pharma jostles for a slice of the weight-loss market
-
BRIEF: InnoCare revenue jumps 37% in 2024 on strong lymphoma drug sales
9969.HK 688428.SHG
- Impression Dahongpao trapped in its one-trick pony performance
-
No respite for RemeGen as problems and losses pile up
9995.HK 688331.SHG
- Cloudbreak Pharma sets sights on Hong Kong IPO after license deal
-
BeiGene heads for profit milestone after hemorrhaging cash
6160.HK ONC.US 688235.SHG
